Life Sciences Archive » June, 2016

Life Sciences - June, 2016

343 articles

• Horizon Fights Par Pharma's Generic Of Urine Disorder Drug
• Health Cos. Paid More To Charity, Nuclear Med Docs In 2015
• Del. Court Tosses $1.2B Philips-Volcano Merger Suit
• $45M Ends Medtronic-NuVasive Patent Saga
• GNC Can't Ax ThermoLife Patent Row
• CVS To Pay $3.5M For Filling 500 Forged Prescriptions
• Mylan Offers Antitrust Fixes To EU For $10B Meda Buy
• Some Fed. Circ. Guidance On Procedural Safeguards For PTAB
• How McDonnell Changes Public Corruption Prosecution
• A Serious Circuit Split On Class Ascertainability
• PerkinElmer Faces Suit Over 'Dismal' Drug Test Devices
• Fla. Co. Settles Abbot Test Strip RICO Suit For $9K
• Whistleblowing Ex-Mylan VP Settles Wrongful Firing Suit
• NY Should Unify Standards For Atty Fees Against State Agency
• Caisse Invests $222.9M In Products Testing Firm Eurofins
• RICO Claims Don't Hold Up In Abbott Off-Label Use Suit
• Affymetrix Investor Settles Suit Over $1.3B Thermo Fisher Sale
• FTC Urges Pa. Judge Not To Extend Deadline For Abbvie Docs
• Hawaii Escapes Plavix MDL Discovery Agreement
• DLA Piper Attys Lied Under Oath About Witness Calls: Judge
• Lamictal Pay-For-Delay Row Shouldn't Be Paused, Buyers Say
• Lipozene Buyer Seeks Class Cert. In False Advertising Row
• Heart Device Maker Pays $8M To End FCA Kickback Suit
• Medtronic Gets Bosch Patent Dismissals Upheld By Fed. Circ.
• Plavix FCA Suit Revived After High Court's Escobar Ruling
• DOJ Confirms Epic Spike In FCA Penalties
• USPTO To Expedite Reviews Of Cancer Treatment Patent Apps
• Arbitrators Overstepped In Biotech IP Row, 3rd Circ. Told
• 3rd Circ. Wants Arguments Limited To Market In Doryx Row
• Biologic Patents Are Under Attack
• 'Kickbacks' In FCA Suit Were Just Discounts, Omnicare Says
• Cooley Adds IP Pros From Pillsbury, MoFo To Calif. Offices
• Monsanto Still In Talks With Bayer After Rejecting $62B Bid
• How To Manage Your Law School Debt After Graduation
• Sanofi Junk Fax Class Asks For Cert In TCPA Row
• The 10 Firms GCs Love For Pharma Work
• 9th Circ. Partially Revives Supplement Suit Against GNC
• Accused 'Snake Oil' Tea Seller Enters Consent Decree
• High Court May Put Limits On Foreign Reach Of US Patents
• FDA, CDC Committee Clash Over Nasal Spray Flu Vaccine Use
• Acclarent Didn't Tell FDA About Adverse Events, Jury Told
• How To Become The Firm Every GC Wants To Hire
• NJ Blood Lab Cops To Role In $100M Referral Scheme
• Hogan Lovells Partner Among 18 Named To Calif. Bench
• The 24 Firms GCs Love The Most
• Celator Investor Looks To Block $1.5B Jazz Pharma Deal
• FDA Sued For Yanking Approval Of Generic Chemo Drug
• Indivior Scores Docs In Suboxone Product-Hopping MDL
• Ex-Zimmer Sales Rep Says Whistleblowing Got Him Canned
• Judge Signs Off On $1B Deal To End Vioxx Marketing Row
• New Vt. Drug Pricing Law Will Have A Limited Impact
• The Firms That Won Big At the Supreme Court
• Ranbaxy: Court Recognizes Fraud-On-The-FDA Antitrust Claim
• The Top Supreme Court Dissents Of The Term
• The Supreme Court Term By The Numbers
• The Funniest Moments Of The Supreme Court's Term
• J&J Unit's Bone Cement Killed Woman In Surgery, Jurors Hear
• A Divided Court Finds New Ways To Be Unanimous
• AstraZeneca Sues FDA To Stop Crestor Generics
• High Court Reins In DOJ With Tightened Bribery Standard
• 8 Wasn't Enough For Lawyers Seeking High Court Clarity
• Attorneys React To High Court's Political Bribery Ruling
• Wright Hip Implant Bellwether Must Be Retried, 11th Circ. Told
• High Court Won't Hear Patent Row Over Fetal DNA Test
• Acclarent Device Quickly Raised Alarms At FDA, Jury Told
• Deals Rumor Mill: China Resources Pharma, Apax, Kuka
• PE-Backed Clinical Trials Co. Medpace Files $150 IPO
• Tobacco Co. Sues Weed Cos. Over 'Marley' Trademark
• The Cloud And Ethical Considerations For Lawyers
• Hunton & Williams Adds IP, Hatch-Waxman Partner In DC
• Send Abilify Compulsive Gambling Suits To Fla.: Consumers
• Sanofi Investors Lose Bid To Revive Kickback Allegations
• Ropes Advises Medtronic's $1.1B Heart Tech Firm Purchase
• A Few Important Decisions From The 'Inferior' Courts
• High Court Vacates Ex-Va. Gov.'s Corruption Conviction
• Justices Will Hear Case On Overseas Reach Of Patent Law
• KaloBios, Shkreli Deal Gets Final OK In Bankruptcy Court
• Supreme Court Asked To Resolve Drug-Fraud RICO Split
• Pfizer Seeks Escape From Lipitor Diabetes MDL Claims
• Pharma Rep Takes Malicious Prosecution Suit To High Court
• Ex-Pharma CEO Says SEC Call For Banishment Too Harsh
• FDA Should Broaden Use Of Real-World Data, Report Says
• Actavis Opposes Further Doc Production In Suboxone MDL
• Biogen Escapes Investor Suit Over Growth Forecasts
• GE Unit Diluted Cell Growth Serum, Stole Buyers, Suit Says
• Watson Wants Lidoderm, Opana Pay-For-Delay Suits Split
• Creating A Partial Solution To Delayed Generic Competition
• How Lawyers Can Harness The Power Of Social Media
• J&J Tells 5th Circ. Hip Implant MDL Is Flawed
• USPTO Director Fires Back At Challenge To AIA Reviews
• Clerical Error Spurs $24M Deal To End Caris Merger Suit
• Norton Rose Fulbright Nabs Partner From Sheppard Mullin
• With Experts Barred, Bayer Says IUD Patients Have No Case
• Teva Agrees To Hold Off On Generic For Diabetes Drug Byetta
• Medicare Part A To Run Out Of Cash In 2028, Trustees Say
• Sandoz Misled About FDA Approval Of Drug, Competitors Say
• Dismissing Drug Design Defect Claims Based On Preemption
• From The Partner's Desk: Tips For Recent Law Grads
• Altaire Can't Dodge Claim GC Lied In Eye-Drop Supply Deal
• Ohio High Court Slams Judge's Overreach In Fen-Phen Case
• Full Fed. Circ. Won't Eye PTAB's Power To Start AIA Reviews
• Inside Trading Suspect's Death Ruled A Suicide
• Nanotech Firm Selecta Biosciences Nets $70M In Upsized IPO
• Atty-Client Privilege At Issue In Meningitis Bellwether
• Calif. Appeals Court Says Skin Care Labeling Deal Was Fair
• Eli Lilly Insurer Denied New Trial In $60M Drug Heist Suit
• Fed. Circ. Won't Revive Forehead Thermometer Patent
• Baxter Wins Chancery OK On New Board Terms, Voting Rules
• Chicago Says High Court Ruling Supports Its Opioid Suit
• Pharmacists Get Prison Over Tainted Compounding Drugs
• Feds Announce Arrests In $900M Medicare Fraud Takedown
• FDA Delay Of Drug Labeling Rule Is Bad News For Plaintiffs
• Alice Turns 2: Fed. Circ. Grapples With 'Implicit Exceptions'
• 'Taking My Talents To South Beach': Law Firm Version
• CVS Deal Would Make Memory Of Supplement Class Action
• Wal-Mart, Kmart, Rite Aid Escape Expired Drug FCA Suit
• FDA Warning Wire: Cancer Doc Targeted Over Plant Conditions
• Analogic Pays Feds $15M To End Russian Bribery Claims
• Sens. Slam 'Anti-Competitive' Wiley Rein Pharma Presentation
• NY Wholesaler Hits Allergan, Others With Antitrust Suit
• Florida Blue To Provide Costly Hep C Drug After Lawsuits
• Your 401(k) Plan: A Ticking Time Bomb Of Liability?
• GNC Investors Double Down In Illegal Supplements Suit
• Full Fed. Circ. Won't Review Generics Jurisdiction Ruling
• A Look At Fed. Circ. Induced Infringement Ruling In NuVasive
• Ex-Pfizer Worker Strikes Insider Trading Deal With SEC
• Not Guilty, Again: Individual Corporate Liability After Reichel
• Andrews Kurth Atty Defends Brief In $445M Dow IP Row
• Senate Rejects Gun Control Measures On DOJ Funding Bill
• Medical Device Maker Must Arbitrate Dispute, NJ Court Says
• Firms Must Plant Roots In These Cities To Compete Globally
• 4 Firms Lead The Pack In Global Expansion
• Law360 Reveals The Global 20 Firms Of 2016
• Ex-Acclarent Execs Slam Gov't's Tactics At Fraud Trial
• Justices Won't Take $4M Globus Medical Trade Secrets Row
• Shareholders Lose Suit Over Glaucoma Drug Trial
• FDA OKs First Human Trials For Zika Vaccine
• J&J Faces Breast-Growth Claims In 5th Philly Risperdal Trial
• Suboxone Buyers Slam Comparison To Sanofi's Antitrust Win
• High Court Seeks US Take On Sandoz-Amgen Biosimilar Battle
• Whistleblowers Lose 1st Circ. Appeal Of Novartis FCA Suit
• 4 Firms To Steer IPOs Led By Year's First VC 'Unicorn'
• Andrews Kurth Atty Can't Crash $446M Dow Row, Bayer Says
• 5 Escape Abbott's Test Strip RICO Suit With Settlement
• Ex-Womble Carlyle Atty Opens Shaw Fishman Del. Office
• Where Pay-For-Delay Stands 3 Years After Actavis
• Greenspoon's Cost Bid In $1.8M Stiefel ERISA Suit Too High
• Janssen Wants To Combine Celltrion Biosimilar Patent Suits
• Colo. Dispensary Urges State AG Intervention In Pot Tax Row
• FedEx Beats Drug Shipping Case As Charges Dropped Midtrial
• Health Hires: Quarles, Sheppard Mullin, Manatt Grow in DC
• Ex-Warner Chilcott Exec Acquitted In Doctor Bribery Scheme
• What To Expect From China's Drug Pricing Investigation
• Alice Turns 2: A Survey Of The Impact Of A 'Minor Case'
• Fed. Circ. Gives AIA Petitioners New Ways To Attack Patents
• Ranbaxy Can't Duck Antitrust Suit Over Generic Applications
• Atty Must Pay For Stolen Fen-Phen Funds: Ky. High Court
• Calif. Jury Finds For Flu Remedy Maker In False Ad Trial
• Health-Focused 1315 Capital Closes 1st Fund At $200M
• FDA Strengthens Kidney Warnings For Diabetes Medicines
• Rimon Adds 4 Partners From Arent, W&C, Sedgwick, Norris
• DJO, Ex-Workers Say Stryker's Poaching Suit Lacks Facts
• Bribery Case Against Ex-Warner Chilcott Exec Heads To Jury
• Senate Panel Moves To Ease Pot Banking Restrictions
• 2nd Circ. Urged To Revive Icahn 'Short-Swing' Trading Suit
• Expanded Access — A Regulatory Balancing Act For Drug Cos.
• Key Fixodent MDL Experts Properly Nixed, 11th Circ. Rules
• Boiron Moves To Toss False Ad Suit Over Flu Remedy Midtrial
• Frustrated FedEx Trial Judge Questions DEA Agent On Day 3
• Jones Day Nabs Tokyo IP Litigation Pro From Ropes & Gray
• Senate Dems' Gun Control Filibuster Halts Funding Debate
• Ferring, Allergan Patent Dispute Will Head To Trial: Judge
• 1st Circ. Won't Revisit $70M Biolitec Sanctions Cap
• J&J Unit Seeks To Boot Invokana Case From Pa. Courts
• Solazyme Urges 3rd Circ. To Back IP Rights Arbitration Award
• Policies Clash In $445M Dow Appeal, Andrews Kurth Atty Says
• KaloBios Plan Confirmed In Tumultuous Ch. 11 Case
• Reed Smith Adds PE, M&A Pro From Winston & Strawn In NY
• What FDA's Drug Distributor Licensing Regs Should Address
• Janssen Hits GE Unit With Patent Suit Over Biosimilar
• Medtronic Ruling Can Steer Transfer Pricing Tax Disputes
• Amneal Tells Fed Circ. Endo Played With Numbers In Patent
• Sens. Unveil New Bill Aimed To Help Generic Drug Flow
• US Weighs In On 1st Circ. Appeal Of Covidien FCA Suit
• Senate Gets Started On $56B Justice-Science-Commerce Bill
• Intuitive's Device Sent Metal To Patients' Brains, Suit Says
• SEC Sues Akebia Manager For Insider Trading On Drug Report
• Jailed Stock Scheme Atty Seeks Indictment Dismissal
• FDA Warning Wire: Sanitary Worries At Whole Foods Plant
• So Long, Seagate: A New Test For Willful Patent Infringement
• PTAB Evidence Rules Clarified, Affirming Genzyme Loss
• FDA OKs Food Draining Device To Treat Obesity
• FDA Issues Final Rule Allowing Symbols On Device Labels
• Warner Chilcott Wants 'Shotgun' Antitrust Claims Tossed
• 6 Factors Every Law Firm's Gender Diversity Initiative Needs
• Ex-Warner Chilcott Exec Says Feds' Jury Directions Flawed
• Patent Cases High Court May Review: Part 2
• Dozens Protest $11.75M Caldera Pelvic Mesh Deal
• Amazon, J&J, Others Pledge To Improve Wage Equality
• Hawaii Says It Can't Be Held To Plavix MDL Discovery Deal
• Firm Tells 3rd Circ. It Doesn't Owe Avandia MDL Fee
• Justices' Enhanced Damages Ruling Gives Patents More Teeth
• Fixodent Users Urge 11th Circ. To Reverse Experts' Exclusion
• Insurer Seeks To Cut Claims After Fresenius' $250M Deal
• 3rd Circ. Questions Allergan Antitrust Dismissal
• Rep Touted Acclarent Device After Promotion Ban, Jury Told
• Snooki, Diet Pill Co. Should Share Gov't Docs, Buyers Say
• FDA Actions 'Inadequate' On Powdered Caffeine, Group Says
• Attorneys React To High Court's Patent Damages Ruling
• Actos Direct Buyers Say Drug Mix Patent Can't Block Generic
• Judge Won't Stay J&J Hip Implant Trials After $502M Verdict
• The Bayer-Monsanto Deal Through An Antitrust Lens
• Shook Hardy Elects 1st Woman To Replace Longtime Leader
• Medivation Slams Sanofi's $9.3B Hostile Takeover Play
• Walgreens Ends Partnership With Blood Testing Co. Theranos
• Teva Halts Headache Patch Sales Amid Patient Burns
• Patent Cases High Court May Review: Part 1
• High Court Relaxes Standard For Enhanced Patent Damages
• Ex-U.S. Rep. To Lead BakerHostetler's Federal Policy Team
• Sex Pill Buyers Denied Cert. Under Spokeo In False Ad Row
• 9th Circ. Urged To Revive GNC Supplement RICO Class Action
• Buyers Say Gleevec Antitrust Suit Should Proceed
• Zimmer Win May Force Harder Look At Runaway Verdicts
• 2 Ex-InSys Staffers Charged Over Fentanyl Kickback Scheme
• Taxation With Representation: Gibson, White, Sheppard
• Purdue Resisting NH Opioid Marketing Probe, AG Says
• Merck To Pay Up To $1.25B For Neurogenic Biotech Afferent
• SEC Takes Off The Gloves Against Digital Casanova's Scheme
• Dental Laser Is Not An Unpatentable Law Of Nature: Judge
• Lone Pine Entered In Zimmer MDL Amid Atty Finger-Pointing
• Investor Sues Immunomedics Over Cancer Drug Misstatements
• Deals Rumor Mill: Bayer, Oaktree Capital, Valeant
• Colombia To Lower Price Of Novartis Cancer Drug Gleevec
• Mass. High Court To Mull VisionAid Counterclaim Coverage
• Chile Wants $15.5M Antitrust Fine For Pfizer Subsidiary
• 5th Circ. Gives Courts Powerful Tool To Enforce Daubert
• In-House Teams Are Voting With Their Feet — And Then Some
• 9th Circ. Probes DOJ On 'Troubling' Medicare Fraud Sentence
• Novartis Gets No Fees Despite 'Exceptional' Patent Case
• Off-Label Use Was Focus Of Training At Acclarent, Rep Says
• Mirena Users Say They Don't Need Experts To Beat Bayer
• Fed. Circ. Upholds Olympus Electrosurgery Patent Win
• Fed Circ. Won't Revive Ex-CEO's $4M Tax Refund Suit
• Potential Class Action Can Proceed In Celexa, Lexapro MDL
• Calif. High Court To Review Novartis Generic Drug Suit
• Royalty Rates in $1.3B Medtronic Row Nixed By Tax Court
• Bass Gets PTAB Review Of Fresenius Diprivan Patent
• FedEx Waives Jury On Eve Of Drug Trafficking Trial
• Boiron Tells False Ad Jury Flu Remedy Is Proven To Work
• 2 Biotechs Price $203M In Stock Offerings To Spur Pipelines
• Valeant Inks $54M Deal In DOJ's Salix Marketing Probe
• Inside Big Pharma's $70M Drug Pricing War In Calif.
• 9th Circ. Affirms Toss Of Suit Over Peregrine Drug Claims
• Ethicon's Own Rep. Said Mesh Degrades In Body, Patients Say
• NY Doctor Gets Prison In $100M Lab Test-Referral Scheme
• Biotech Co. Dodges Shareholder Suit Over 'Hyped' Drugs
• Marketing Came Before Research At Acclarent, Doc Testifies
• Biotech-Focused Longitude Capital Closes $525M Fund
• UPenn Trustees Call Inter Partes Reviews Unconstitutional
• 3rd Circ. Won't Take Second Look At Lovenox Antitrust Suit
• 7 Tips For Writing An Effective Amicus Brief
• The 25 Law Firms GCs Recommend To Their Friends
• 6 Funds Chip In $100M For 'Organism Design Co.' Startup
• Machine-Learning Algorithms Can Help Health Care Litigation
• 5 Insights From Garden City Group GC Scott Nader
• Sequenom Eyes Australia In Patent Row Over Fetal DNA Test
• Boiron Flu Remedy 'Expensive Sugar,' False Ad Jury Hears
• Murder, RICO Charges Remain In Meningitis Outbreak Suit
• J&J Unit Says $8.3M Hip Implant Verdict Inconsistent
• Trial Kicks Off Over Sanofi's IP Claims Over Generic Multaq
• Abbott Settles Depakote Suit As Jury Deliberates
• Ex-CEO Urges Fed. Circ. To Revive Bid For $4M Tax Refund
• FDA Warning Wire: Zimmer Biomet, Spotty Donor Screening
• FDA Can't OK More Crestor Generics, AstraZeneca Says
• Justices Urged To Clarify Natural Phenomena Patent Test
• NuVasive Can't Shake $28M Unfair Competition Verdict
• KaloBios Ties Up Loose Ends For Ch. 11 Plan Confirmation
• AngioScore's $20M Award Came In Wrong Suit, Fed. Circ. Told
• Baker & McKenzie Nabs Ex-K&L Gates Int'l Arbitration Pro
• Ex-Execs Blame FDA Rules In Off-Label Fraud Trial
• Anatomy Of A Merger: Grit Helps Shire Seal $32B Baxalta Buy
• White & Case Guides Zimmer Biomet In $1B Deal For LDR
• Russian Firm Hits Roche With Cancer Generics Antitrust Suit
• CPSC Urges Gov't To Sue Dr. Reddy's Over Drug Packaging
• Merck Atty's Lies Unravel $200M Patent Win Against Gilead
• Pfizer Opioid Meant To Deter Abuse Has Tampering Risk: FDA
• Greenspoon Marder Grows Cannabis Practice Across West
• 1st Circ. Urged To Revive CVS Vitamin E Label Suit
• Genentech, OSI Ink $67M FCA Deal Over Cancer Drug Claims
• Cancer-Focused Biotech Syros Files For $69M IPO
• J&J Won't Have To Avoid New Ads Before Liver Damage Trial
• Shkreli, Ex-Kaye Scholer Atty Deny New Fraud Charge
• Del. Justices Uphold $16M Caris Judgment In Split Decision
• Deals Rumor Mill: Pfizer, Constellis Holdings, Kuka
• Abbott Loses Final Appeal Of $3.4M Portuguese Antitrust Fine
• Actos Buyers Cite 2nd Circ. Libor Case In Antitrust Appeal
• Zimmer Gets $20M Knee Injury Verdict Trashed In Pa.
• Justices Refuse GSK's Appeal In Avandia RICO Case
• PE Investors Plug $100M Into NY-Based Cancer Treatment Co.
• High Court Seeks US Views On Lamictal Pay-For-Delay Case
• 5 Steps To An Anti-Corruption 'Culture Of Compliance'
• Ex-Stiefel CFO Urges Justices To Review Securities Fraud Suit
• Indivior Claims Victory In Patent Row With Actavis, Par
• Endo's AMS Settles More Than 100 Suits In Pelvic Mesh MDL
• Fed Circ. Backs NuVasive Surgical Patent Win Post-Commil
• Vermont Gov. Signs Drug Price Transparency Bill
• Cymbalta Users Urge Revival Of Drug's Withdrawal Claims
• Health Hires: Ex-HHS Atty Joins Hogan Lovells
• PTAB Will Review Eli Lilly's Patent For Cancer Drug Alimta
• Bayer Loses EPA Row Over Axed Pesticide
• Justices Told Hatch-Waxman Patent Safe Harbor Too Narrow
• Ex-Oppenheimer Adviser Charged With Insider Trading
• FDA Beats Spectrum Suit Over Fusilev Exclusivity At DC Circ.
• Ferring Hit With Class Action Over Weak IVF Drug
• 6 Supreme Court Cases Every BigLaw Attorney Should Watch
• How Eisai V. Sanofi Will Affect Loyalty Discount Cases
• Forest Escapes Class Cert. In Antidepressant Marketing MDL
• NantHealth's $91M Deal Leads 2 Biotech IPOs Totaling $141M
• Bristol-Myers Asks Calif. High Court To Block Plavix Suits
• KaloBios Puzzled By Hospital's Contract Decision Demand
• Teva Headache Patch Has Burned Many Patients, FDA Says
• Medical Device Co. Sued In Delaware Over Fee-Shifting Bylaw
• A Brief History Of Law Firm Cyberattacks
• 7th Circ. Urged To Review Disclosure-Only Settlements
• Mom Tells 6th Circ. Depakote Birth Defect Trial Court Erred
• Prior Art: When On Sale Is Not 'On Sale'
• BioScrip Board Shuffle Toppled Shareholder Suit, Judge Says
• Masimo Asks Justices To Review Arbitrator Bias Row
• Dow Urges Fed. Circ. To Nix $456M Patent Arbitration Award
• Valvoline Leads Way As 2 Cos. File For IPOs Totaling $150M
• In Rare Move, Judge Orders Zimmer Plaintiffs To Prove Cases
• Firm Says Jury Erred In Denying Claims For $1M In Legal Fees
• Drug Co. Hit With Class Action Over FDA Approval Claims
• CalPERS Backs Merck Investors In 3rd Circ. Tolling Fight
• Fla. Court OKs Stricter Expert Standard For Pending Cases
• Class Can't Redefine Trial Terms In Boiron False Ad Suit
• Shareholders Say Auspex CEO Rushed $3.5B Teva Merger
• Exergen Denied Enhanced Damages In $14.6M Patent Fight
• Feds Net $9M FCA Deal From Tenn. Drug Testing Co., Doc
• Ex-Execs Say 1st Amendment Protects Off-Label Promotion
• Pa. Readies 1st Interim Regulation For Medical Pot
• Patent Difficulties For 3-D Printed Medical Implants
• FDA's Opioid Implant Nod Shows Pressure To Curb Addiction